For cancer patients, every unnecessary imaging procedure carries real costs — radiation exposure, contrast-induced kidney stress, logistical burden during already intensive treatment schedules. A validated clinical decision tool that could safely reduce the frequency of CT pulmonary angiography in this population would represent a meaningful practical advance, particularly given how often venous thromboembolism complicates cancer care.
Published in JAMA, this prospective study evaluated the YEARS algorithm — a three-criteria clinical decision rule combined with D-dimer thresholds — against standard-of-care CTPA in patients with active cancer and suspected pulmonary embolism. The algorithm stratifies patients by the presence of classic PE signs, alternative diagnosis likelihood, and hemoptysis, then applies variable D-dimer cutoffs to determine whether imaging is truly necessary. The trial enrolled several hundred cancer patients across multiple centers, finding that applying the YEARS algorithm safely excluded PE without imaging in a meaningful proportion of patients, while the 3-month thromboembolic event rate among those in whom PE was ruled out remained non-inferior to scan-first approaches.
This finding matters within a specific clinical context. Cancer patients present a diagnostic challenge because their D-dimer levels are chronically elevated by malignancy itself, theoretically reducing the specificity of D-dimer-based algorithms. Prior validation of YEARS was conducted largely in general ED populations, making this cancer-specific evaluation an important incremental contribution rather than a paradigm shift. The study's strength lies in its prospective, multicenter design and clinically relevant endpoint. Key limitations include the heterogeneity of cancer types and treatment stages within the cohort, and the question of whether results generalize across different healthcare settings. For clinicians, this adds useful evidence that structured clinical decision rules can responsibly reduce imaging burden even in high-risk oncology populations — a confirmatory but clinically valuable finding.